UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Integrins as A New Target for Cancer Treatment

Anti-cancer agents in medicinal chemistry, 2019-01, Vol.19 (5), p.580-586

2019

Volltextzugriff (PDF)

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

Journal of clinical oncology, 2013-02, Vol.31 (5), p.616-622

2013

Volltextzugriff (PDF)

Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma

Journal of clinical oncology, 2013-03, Vol.31 (9), p.1211-1218

2013

Volltextzugriff (PDF)

A Clinical Outcome of the Anti-PD-1 Therapy of Melanoma in Polish Patients Is Mediated by Population-Specific Gut Microbiome Composition

Cancers, 2022-10, Vol.14 (21), p.5369

2022

Volltextzugriff (PDF)

Oncogenic Role of ZFAS1 lncRNA in Head and Neck Squamous Cell Carcinomas

Cells (Basel, Switzerland), 2019-04, Vol.8 (4), p.366

2019

Volltextzugriff (PDF)

Interference of COVID-19 Vaccination With PET/CT Leads to Unnecessary Additional Imaging in a Patient With Metastatic Cutaneous Melanoma—Case Report

Frontiers in oncology, 2021-08, Vol.11

2021

Volltextzugriff (PDF)

Impact of Bisphosphonate Therapy on Oral Health in Patients with Breast and Prostate Cancer and Bone Metastases: A Comprehensive Study

Cancers, 2024-03, Vol.16 (6), p.1124

2024

Volltextzugriff (PDF)

Diagnostic and prognostic role of long non-coding RNAs (lncRNAs) in metastatic melanoma patients with BRAF gene mutation receiving BRAF and MEK inhibitors

Heliyon, 2024-04, Vol.10 (7), p.e29071-e29071, Article e29071

2024

Volltextzugriff (PDF)

Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma

Contemporary oncology (Poznań, Poland), 2017-01, Vol.1 (1), p.1-5

2017

Volltextzugriff (PDF)

Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck

Anti-cancer agents in medicinal chemistry, 2019-01, Vol.19 (3), p.290-303

2019

Volltextzugriff (PDF)

Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy

Cells (Basel, Switzerland), 2023-03, Vol.12 (5), p.789

2023

Volltextzugriff (PDF)

Basal Cell Carcinoma: Pathology, Current Clinical Treatment, and Potential Use of Lipid Nanoparticles

Cancers, 2022-06, Vol.14 (11), p.2778

2022

Volltextzugriff (PDF)

Healing Process after High-Intensity Focused Ultrasound Treatment of Benign Skin Lesions: Dermoscopic Analysis and Treatment Guidelines

Journal of clinical medicine, 2024-02, Vol.13 (4), p.931

2024

Volltextzugriff (PDF)

Design of clinical trials for therapeutic cancer vaccines development

European journal of pharmacology, 2009-12, Vol.625 (1), p.84-89

2009

Volltextzugriff (PDF)

Therapeutic melanoma vaccine with cancer stem cell phenotype represses exhaustion and maintains antigen-specific T cell stemness by up-regulating BCL6

Oncoimmunology, 2020-01, Vol.9 (1), p.1710063-1710063

2020

Volltextzugriff (PDF)

Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma

Medicine (Baltimore), 2015-05, Vol.94 (21), p.e853

2015

Volltextzugriff (PDF)

PRINS lncRNA Is a New Biomarker Candidate for HPV Infection and Prognosis of Head and Neck Squamous Cell Carcinomas

Diagnostics (Basel), 2020-09, Vol.10 (10), p.762

2020

Volltextzugriff (PDF)

lncRNA in HNSCC: challenges and potential

Contemporary oncology (Poznań, Poland), 2017-01, Vol.21 (4), p.259-266

2017

Volltextzugriff (PDF)

Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma

The Journal of dermatological treatment, 2022-05, Vol.33 (4), p.2168-2174

2022

Volltextzugriff (PDF)

Functional T Cell Reactivity to Melanocyte Antigens Is Lost during the Progression of Malignant Melanoma, but Is Restored by Immunization

Cancers, 2021-01, Vol.13 (2), p.223

2021

Volltextzugriff (PDF)

Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results

Journal for immunotherapy of cancer, 2018-11, Vol.6 (1), p.134-134, Article 134

2018

Volltextzugriff (PDF)

Circulating Melanoma Cell Numbers Correlate with TIGIT-Positive Cytotoxic T Cell Counts in Advanced-Stage Melanoma Patients

Cells (Basel, Switzerland), 2023-03, Vol.12 (6), p.856

2023

Volltextzugriff (PDF)

Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients

Oncoimmunology, 2018-11, Vol.7 (11), p.e1509821-e1509821

2018

Volltextzugriff (PDF)

1 – 25 von 187

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(180)
Mit Volltextzugriff
(150)

Publikationsform

Sprache

Englisch
(185)
Polnisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(128)
Life Sciences & Biomedicine
(120)
Humans
(77)
Oncology
(56)
Female
(51)
Adult
(41)
Middle Aged
(40)
Male
(39)
Melanoma
(37)
Immunotherapy
(33)
Aged
(27)
Public, Environmental & Occupational Health
(26)
Environmental Sciences
(25)
Environmental Sciences & Ecology
(25)
Dust
(20)
Metastasis
(19)
Patients
(19)
Occupational Exposure
(16)
Poland
(16)
Pantoea Agglomerans
(15)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Integrins as A New Target for Cancer Treatment

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma

A Clinical Outcome of the Anti-PD-1 Therapy of Melanoma in Polish Patients Is Mediated by Population-Specific Gut Microbiome Composition

Oncogenic Role of ZFAS1 lncRNA in Head and Neck Squamous Cell Carcinomas

Anticancer immunotherapy by CTLA-4 blockade： obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25

Interference of COVID-19 Vaccination With PET/CT Leads to Unnecessary Additional Imaging in a Patient With Metastatic Cutaneous Melanoma—Case Report

Impact of Bisphosphonate Therapy on Oral Health in Patients with Breast and Prostate Cancer and Bone Metastases: A Comprehensive Study

Diagnostic and prognostic role of long non-coding RNAs (lncRNAs) in metastatic melanoma patients with BRAF gene mutation receiving BRAF and MEK inhibitors

Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma

Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck

Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy

Basal Cell Carcinoma: Pathology, Current Clinical Treatment, and Potential Use of Lipid Nanoparticles

Healing Process after High-Intensity Focused Ultrasound Treatment of Benign Skin Lesions: Dermoscopic Analysis and Treatment Guidelines

Design of clinical trials for therapeutic cancer vaccines development

Therapeutic melanoma vaccine with cancer stem cell phenotype represses exhaustion and maintains antigen-specific T cell stemness by up-regulating BCL6

Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma

PRINS lncRNA Is a New Biomarker Candidate for HPV Infection and Prognosis of Head and Neck Squamous Cell Carcinomas

lncRNA in HNSCC: challenges and potential

Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma

Functional T Cell Reactivity to Melanocyte Antigens Is Lost during the Progression of Malignant Melanoma, but Is Restored by Immunization

Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results

Circulating Melanoma Cell Numbers Correlate with TIGIT-Positive Cytotoxic T Cell Counts in Advanced-Stage Melanoma Patients

Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients

Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF/MEK Targeted Therapy: Multicenter Real-World Report

Suchergebnisse filtern